(Q36186934)

English

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. (English)

1 reference

Europe PubMed Central

12 August 2017

author name string

Ahmad A Tarhini

1

1 reference

Europe PubMed Central

12 August 2017

Joseph Stuckert

2

1 reference

Europe PubMed Central

12 August 2017

Sandra Lee

3

1 reference

Europe PubMed Central

12 August 2017

Cindy Sander

4

1 reference

Europe PubMed Central

12 August 2017

John M Kirkwood

5

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

1 December 2008

1 reference

Europe PubMed Central

12 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

12 August 2017

27

1 reference

Europe PubMed Central

12 August 2017

38-44

1 reference

Europe PubMed Central

12 August 2017

1

1 reference

Europe PubMed Central

12 August 2017

A review of the S100 proteins in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Elevated serum levels of S100 and survival in metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

1 October 2017

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Evaluation of new putative tumor markers for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

2 July 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426933

23 September 2018

S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Two Prognostic Markers for Malignant Melanoma: MIA and S100 β

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the release and half-life of S100B protein in the peripheral blood of melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

S100B protein detection in serum is a significant prognostic factor in metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of serum S-100B in malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four different assays for determination of serum S-100B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19047287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.17.1777

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36186934&oldid=1520459685"